Phase II Study of Arsenic Trioxide in Patients With Multiple Myeloma
OBJECTIVES: I. Determine the response rate of patients with relapsed or refractory stage II
or III multiple myeloma treated with arsenic trioxide. II. Determine the overall and
relapse-free survival rates of patients treated with this drug. III. Determine the safety
profile of this drug in these patients.
OUTLINE: Patients receive arsenic trioxide IV on days 1-5 and 8-12. Treatment repeats every
4 weeks for up to 6 courses. Patients are followed at 4 weeks after the last treatment dose.
PROJECTED ACCRUAL: A total of 55 patients will be accrued for this study.
Interventional
Primary Purpose: Treatment
Carolyn Paradise, MD
Study Chair
Cell Therapeutics
United States: Federal Government
CDR0000068688
NCT00017433
January 2001
Name | Location |
---|---|
Swedish Cancer Institute | Seattle, Washington 98104 |
Cleveland Clinic Taussig Cancer Center | Cleveland, Ohio 44195 |
Scripps Clinic | La Jolla, California 92037 |
University of Illinois at Chicago | Chicago, Illinois 60612 |
Rocky Mountain Cancer Center | Denver, Colorado 80218 |
Georgia Cancer Specialist | Marietta, Georgia 30060 |